Madrigal Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDGL research report →
Range $533 – $962
Price Chart
About the company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH).
- CEO
- William J. Sibold
- IPO
- 2007
- Employees
- 915
- HQ
- West Conshohocken, PA, US
Get TickerSpark's AI analysis on MDGL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.81B
- P/E
- -64.15
- Fwd P/E
- 54.19
- PEG
- -1.15
- P/S
- 6.17
- P/B
- 17.69
- EV/EBITDA
- -70.99
- Div Yield
- 0.00%
- Gross Margin
- 90.96%
- Op Margin
- -10.69%
- Net Margin
- -10.89%
- ROE
- -27.07%
- ROIC
- -15.56%
Latest fiscal year · YoY change
- Revenue
- $958.40M+432.1%
- Gross Profit
- $902.25M+418.8%
- Op Income
- $-300,097,000
- Net Income
- $-288,284,000+38.1%
- EPS
- $-12.85+41.3%
- OCF Growth
- +58.4%
- FCF Growth
- +58.4%
- 52W High
- $615.00
- 52W Low
- $353.54
- 50D MA
- $465.44
- 200D MA
- $494.50
- Beta
- -1.00
- RSI (14)
- 26
- Avg Volume
- 367.76K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Madrigal posted another strong Rezdiffra launch quarter, with $431 million in Q3 net sales, its first profitable quarter, and a more aggressive push into F4c MASH.· November 3, 2026
- Q3 net sales were $431.3 million, up 50% year over year, and year-to-date net sales reached $1.1 billion.
- Active Rezdiffra patients rose to more than 55,850, versus more than 29,500 a year ago.
- Management said the U.S. F2/F3 MASH market is on track to grow more than 30% this year, with diagnosed patients now above 530,000.
- The company announced a second F4c phase III outcomes study, MAESTRO-CSPH, with more than 2,000 planned patients and about 3,000 patients across the two F4c outcomes trials.
- Madrigal reported its first quarter of profitability and ended Q3 with $961.8 million in cash.
Third quarter 2026 net sales were $431.3 million, up 50% year over year, with year-to-date net sales of $1.1 billion. Net income was $55.4 million versus a net loss of $114.2 million a year ago. Cost of sales was $37.8 million versus $18.1 million; R&D was $71.8 million versus $174 million; and SG&A was $265.7 million versus $209.1 million. Gross-to-net is expected to land at the low end of the company's mid-to-high 30% range for 2026, and full-year 2026 R&D is expected to be nominally lower than 2025 while SG&A is expected to increase. For 2027, management said it is too early for specific guidance, but it expects continued strong growth and said gross-to-net next year should be around the high end of the 2026 range, with quarterly Q1 seasonality still expected.
Bill Sibold framed the quarter as evidence that Rezdiffra is becoming the foundational MASH therapy, saying the company is ‘firing on all cylinders’ and already annualizing at more than $1.7 billion based on Q3 results. He emphasized that the market is still early, diagnosis and penetration remain low, and the opportunity could expand further as F4c develops. His tone was highly confident and competitive, repeatedly stressing a ‘first and best’ strategy, a long patent runway into 2045, and the view that Madrigal is building a mega-blockbuster franchise.
Mardi Dier highlighted the financial strength of the launch, noting Q3 net sales of $431.3 million, year-to-date net sales of $1.1 billion, and the first quarter of profitability at $55.4 million of net income. She said gross-to-net should end 2026 at the low end of the mid-to-high 30% range, helped by strong demand and disciplined management, and that the company expects Q4 SG&A to be higher than Q3 due to timing of marketing spend. She also said the company ended the quarter with $961.8 million of cash, has been operating cash flow positive for the last two quarters, and remains well resourced to fund Rezdiffra, pipeline work, and additional business development.
Analysts focused on Q4 sales momentum, the new MAESTRO-CSPH trial, event timing in MAESTRO-NASH OUTCOMES, Medicare Part D contracting, and whether GLP-1 use is affecting Rezdiffra. Management said Q4 should continue to show steady patient adds and that growth from Q3 to Q4 should be consistent with consensus, while also stating MAESTRO-NASH OUTCOMES is now expected in late 2027 and dropout rates are within expectations. On the F4c program, management said the new trial is intended to be more practice-shaping, enrich more effectively for CSPH, and support labeling discussions with FDA.
The call supported a bull case that Rezdiffra is still in early innings: sales grew 50% year over year, patient counts nearly doubled versus last year, and management said the diagnosed market is expanding rapidly. The company also now has cash flow positivity, a large cash balance, and a broader F4c development program that could extend the franchise if outcomes data are positive.
The main risks discussed were that F4c outcomes remain event-driven and uncertain, with MAESTRO-NASH OUTCOMES not expected until late 2027 and MAESTRO-CSPH only starting in the first half of 2027. Management also flagged continued dependence on launch execution, quarter-to-quarter SG&A volatility, gross-to-net pressure from Medicare Part D contracting, and the possibility that late-stage cirrhosis populations may be harder to study and treat than earlier-stage patients.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.2%
- Shares Outstanding
- 23.23M
- Float Shares
- 21.66M
of shares held by institutions
441 13F filers
Buy/sell ratio 5.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for MDGL, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 2.14M | ▲ 1.43K |
| Janus Henderson Group Ltd. | 2.02M | ▲ 433.80K |
| Rtw Investments, LP | 1.99M | 0 |
| Jupiter Topco LLC | 1.94M | ▲ 1.94M |
| Avoro Capital Advisors LLC | 1.83M | ▲ 15.15K |
| Vanguard Group Inc | 1.81M | ▼ 3.16K |
| Paulson & Co. Inc. | 1.34M | ▼ 52.17K |
| Blackrock, Inc. | 1.24M | ▲ 38.29K |
| Vanguard Capital Management LLC | 846.64K | ▲ 10.97K |
| Wellington Management Group Llp | 825.71K | ▲ 130.76K |
| Vanguard Portfolio Management LLC | 761.02K | ▼ 20.71K |
| State Street Corp | 595.77K | ▲ 68.72K |
Held by 458 ETFs
Biggest fund positions in MDGL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | BAKER BROS. ADVISORS LP | buy | 2,000 |
| Nov 6, 26 | BAKER BROS. ADVISORS LP | buy | 13,740 |
| Nov 6, 26 | BAKER BROS. ADVISORS LP | buy | 60,400 |
| Nov 4, 26 | BAKER BROS. ADVISORS LP | buy | 10,080 |
| Nov 4, 26 | BAKER BROS. ADVISORS LP | buy | 5,586 |
| Nov 6, 26 | Kelley Shannon T | sell | 1,077 |
| Sep 9, 26 | Sibold William John | sell | 131 |
| Sep 9, 26 | Sibold William John | sell | 347 |
| Sep 9, 26 | Sibold William John | sell | 522 |
| Sep 9, 26 | Sibold William John | sell | 368 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MDGL coverage
Recent articles, reports, and earnings notes.

What to Watch as Retension Pharmaceuticals Prices on Nasdaq
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is expected to list on 2026-10-09, and the company has not disclosed a price range. The IPO is priced, with 3,300,000 shares offered and a disclosed market cap of $41.25 million. The setup is straightforward: shareholders should watch whether RTN-001’s Phase 2b data can support a larger hypertension story, but the stock still carries classic single-asset biotech risk.

Devonian Health Group IPO: The Bull and Bear Case
Devonian Health Group Inc. (NYSE: DHGR) is expected to list on 2026-08-21, but the company has not disclosed a price range yet. The setup is a clinical-stage biotech story with a commercial distribution business behind it, which gives it a real revenue base but also a financing-heavy path ahead.

Should You Buy the Palatin Technologies IPO? Here's the Setup
Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.
Want a deeper read on MDGL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
MDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
globenewswire.com · Nov 20
MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns
prnewswire.com · Nov 19
Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH
businesswire.com · Nov 19
Kaplan Fox Reminds Madrigal Pharmaceuticals, Inc. (MDGL) Investors of an Investigation into Potential Securities Law Violations
newsfilecorp.com · Nov 19
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 18
Kaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations
globenewswire.com · Nov 18
Madrigal Pharmaceuticals, Inc. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your MDGL Investments
newsfilecorp.com · Nov 18
Kaplan Fox & Kilsheimer LLP Alerts Investors of Madrigal Pharmaceuticals, Inc. (MDGL) to an Investigation of Potential Securities Law Violations
newsfilecorp.com · Nov 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.